Epigenetic Modifications of Histones: Impact on Chromatin Structure and Gene
Regulation
Introduction
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
Packaging vast genomes into orderly chromatin architectures poses unique regulatory
challenges cleverly overcome by cells. One solution involves dynamically controlling
chromatin structure and accessibility through post-translational modifications of histone
proteins circumscribing DNA into nucleosomes. These epigenetic histone marks create a
highly-regulated code modulating transcriptional responses to both intrinsic and
environmental signals during development, homeostasis and disease pathogenesis. Advancing
tools now reveal novel histone modifications expanding regulation's complexity and medical
implications. This review surveys diverse histone modifications, their biological functions
dictating gene expression states and prospects for therapeutic targeting in various disease
contexts.
Histone Covalent Modifications
Four core histone proteins - H2A, H2B, H3 and H4 - project positively-charged N-termini as
docking sites amenable to an array of covalent post-translational tail modifications including:
- Methylation catalyzed by histone methyltransferases adding one to three methyl residues
mainly on H3K4, H3K9, H3K27 and H3K36.
- Acetylation deposited by histone acetyltransferases neutralizing charge and relaxing
chromatin at H3K9, H3K14, H3K18 and H3K27 residues.
- Phosphorylation via histone kinases regulating processes like DNA damage response
through H2AX S139 phosphorylation.
- Ubiquitination performed by Polycomb/RING1B complexes catalyzing H2AK119Ub
involved in gene silencing.
- Sumoylation, ADP-ribosylation and deimination at specific histone sites constitute lesser-
studied yet functionally-relevant marks.
Over 100 modifications altogether encode transcriptional programs through combinatorial
complexity exceeding DNA codes alone.
Interpreting the Histone Code
Epigenetic "readers" differentially interpret alteration-encoded information:
- Bromodomain proteins selectively recognize acetyl-lysine interactions regulating processes
like inflammation andtumorigenesis.
- Chromodomains and Tudor domains preferentially distinguish methylation states
controlling pluripotency, hematopoiesis and cancer stemness.
- MBT repeat proteins and PHD fingers bind both methylated and unmodified histone
sequences in development and disease.
"Eraser" enzymes specifically hydrolyze marks like histone deacetylases, demethylases and
phosphatases maintaining controlled mark dynamics.
Transcriptional outputs are thus finely tuned by integrated networks interpreting
combinatorial histone codes in flexible, context-dependent ways rather than static on/off
states.
Modulation through the Cell Cycle
Histone modifications guide orderly progression through cellular differentiation, replication
and division cycles:
- Proliferation markers like H3K4me3 and H3K27ac demarcate actively transcribed genes
promoting duplicative amplification.
- H3K9me3, H3K27me3 and Polycomb repressive complexes silence developmental
regulators and tumor suppressors during self-renewal.
- Cohesin complex phosphorylation dictating sister chromatid adhesion is cell cycle-
regulated.
- H3 phosphorylation by Aurora B kinase triggers chromatin condensation prior to division.
- DNA replication enzymatically replaces modifications on parental histones ensuring
integrity of epigenetic programming into daughter cells.
Sequential, spatially-organized histone regulation thus underpins faithful multi-generational
transmission of cellular identities and functions.
Modulating Chromatin Structure
Histone modifications alter nucleosome/chromatin configurations fundamentally impacting
DNA-templated processes:
- Acetyl/methyl-lysine marks loosen internucleosomal interactions by counteracting histone
positive charge compaction effects.
- Phosphorylation recruits effector proteins propagating structural changes over larger
territories.
- Ubiquitin recruits ATP-dependent chromatin remodelers like SWI/SNF complexes
sliding/ejecting nucleosomes in an ATP-fueled manner.
- Linker histone H1 regulates higher-order chromatin folding through modulation of its
binding affinity.
- ADP-ribosylation adds bulky, negatively-charged moieties promoting euchromatin
decompaction at DNA damage sites.
Such structural modulations coordinately regulate accessibility for factors like RNA
polymerases, insulators, enhancers and repair machinery underlying transcriptional
permissiveness versus silencing at individual loci.
Memory Maintenance through Mitotic Inheritance
Faithful epigenetic propagation across cellular divisions entails maintenance mechanisms
acting during DNA replication/mitosis:
- Histone chaperones like CAF1 deposit unmodified H3.1/H4 tetramers ahead of replication
forks preserving nucleosomal integrity.
- Methyltransferase complexes containing UHRF1 recognize hemimethylated CpG sites post-
replication to restore H3K9me3 repressive marks.
- PRC2 Polycomb complexes redistribute H3K27me3 silencing marks after mitosis via non-
coding RNA targeting.
- Trithorax group proteins sustain developmental gene activation states across generations
through H3K4/K36 methylation.
- Histone modifications themselves guide cohesin/condensin architecture remodeling during
mitotic chromosome segregation.
Such self-reinforcing networks lock differentiation decisions in place permanently yet permit
environmental adaptation through ongoing dynamic mark modulation.
Epigenetic Remodeling in Disease
Aberrant histone regulation features prominently across diverse disease contexts requiring
continued mechanistic elucidation:
- Cancer genomes harbor global hypomethylation/hypermethylation patterns inducing
oncogenic programs through chromatin deregulation.
- Autoimmune conditions involve autoantibodies recognizing peculiar post-translational
histone modifications.
- Neurodegenerative disorders exhibit region-specific losses of acetylation/methylation
associated with transcriptional dysregulation.
- Metabolic dysfunction links histone modifications altering expression of key
gluconeogenic/adipocyte genes to complications like diabetes, obesity and non-alcoholic fatty
liver disease.
- Imprinting disorders display parent-of-origin DNA methylation defects during germline
reprogramming disrupting monoallelic expression programs.
Further characterizing causal links between chromatin imbalances and pathogenesis informs
epigenetic therapeutic strategies.
Targeting the Histone Code Therapeutically
Based on comprehension gained, several approaches offer corrective strategies by modulating
histone-modifying activities:
- Histone deacetylase inhibitors reverse gene silencing abnormalities in cancers, viral
infection, heart disease and certain neurodegenerative conditions.
- DOT1L inhibitors target disruptive mixed lineage leukemia gene fusions creating H3K79
hypermethylation in leukemia.
- EZH2 inhibitors restore normal Polycomb silencing functions abrogated in certain
lymphomas, mesothelioma and medical epithelial cancers.
- Lysine-specific demethylase inhibitors counteract deregulated demethylation mediated by
KDM5 family members in neurodevelopmental disorders.
- DNA methyltransferase inhibitors reactivate silenced tumor suppressors epigenetically
inactivated in myelodysplastic syndromes and certain solid tumors.
With ongoing innovation, epigenetic therapies may one day target pathogenic chromatin
remodeling more precisely.
Concluding Remarks
Collectively, coordinated patterns of histone tail modifications conferring distinct
structural/electrostatic properties act as a highly regulated code driving controlled, reversible
changes in chromatin architecture and transcriptional accessibility on a massive scale.
Dysregulation in epigenetic programming has emerged as a widespread driver of disease
pathogenesis demanding ever more sophisticated understanding. Continued progress
promises deeper mechanistic insights empowering rational design of safe, targeted histone-
modifying therapeutics across broad disease categories. By elucidating regulatory layers
intertwined with DNA, epigenetics holds promise for both illuminating basic biological
regulation and advancing medical innovations.
